Compare CHR & HCWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHR | HCWB |
|---|---|---|
| Founded | 2016 | 2018 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6M | 3.6M |
| IPO Year | 2018 | 2021 |
| Metric | CHR | HCWB |
|---|---|---|
| Price | $1.36 | $1.10 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 85.4K | ★ 86.0K |
| Earning Date | 07-28-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | N/A | ★ $4,099,750.00 |
| Revenue This Year | $105.44 | $12,215.61 |
| Revenue Next Year | $30.02 | N/A |
| P/E Ratio | $22.87 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.03 | $0.86 |
| 52 Week High | $2.95 | $23.94 |
| Indicator | CHR | HCWB |
|---|---|---|
| Relative Strength Index (RSI) | 44.14 | 32.80 |
| Support Level | $0.73 | $1.12 |
| Resistance Level | $1.69 | $1.73 |
| Average True Range (ATR) | 0.13 | 0.09 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 33.78 | 13.89 |
Cheer Holding Inc is a provider of next generation mobile internet infrastructure and platform services in China. It is engaged in building a digital ecosystem that integrates platforms, applications, technology, and industry into a cohesive system, thereby creating a new, open business environment that leverages AI technology. Its portfolio includes various products and services, such as Polaris Intelligent Cloud, CHEERS Telepathy, CHEERS Open Platform, CHEERS Video, CHEERS e-Mall, CheerCar, CheerChat, CHEERS Fresh Group-Buying E-commerce Platform, Digital Innovation Research Institute, CHEERS Livestreaming, variety show series, IP short video matrix, and more.
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.